Share Buybacks

On 27 February 2025, Haleon plc announced a capital allocation of £500 million for share buybacks during 2025. 

On 21 March 2025, Haleon completed an off-market buyback of c. 44m shares from Pfizer Inc for approximately £170m.

On 28 March 2025, we announced the commencement of a share buyback programme for up to £330m. This represents the remainder of the £500m allocated to share buybacks in 2025. The first tranche of the buyback programme commenced on 28 March 2025 for an aggregate consideration of c. £200m and concluded on 26 June 2025 with Haleon re-purchasing c. 51m shares. 

On 31 July 2025, we announced the commencement of the second tranche of the buyback programme for an aggregate consideration of c. £280m. This was made up of c. £130m to complete the remainder of the £500m allocated to share buybacks in 2025 and a further c. £150m for the purposes of satisfying Haleon's obligations under its existing employee share plans in 2026 and 2027. The second tranche of the buyback programme concluded on 1 October 2025 with Haleon re-purchasing c. 80.6m shares. 

On 29 February 2024, Haleon plc announced a capital allocation of £500 million for share buybacks during 2024.

We returned £500m to shareholders through off-market buybacks of shares from Pfizer Inc. of £315m and £115m in March and October 2024, respectively, with the remaining £70m completed through an on-market buyback programme which commenced on 1 August 2024 and ceased on 1 October 2024.